Interagency Coordinating Committee on the Validation of Alternative Methods; Notice of Public Meeting; Request for Public Input, 14867-14869 [2018-07057]
Download as PDF
<![CDATA[
daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 67 / Friday, April 6, 2018 / Notices
effectively reducing morbidity and
mortality in newborns and children
having or at risk for heritable disorders.
In addition, the Committee provides
advice and recommendations to the
Secretary concerning the grants and
projects authorized under section 1109
of the PHSA and technical information
to develop policies and priorities for
grants, including those that will
enhance the ability of the state and local
health agencies to provide for newborn
and child screening, counseling and
health care services for newborns, and
children having or at risk for heritable
disorders.
The Committee reviews and reports
regularly on newborn and childhood
screening practices for heritable
disorders, recommends improvements
in the national newborn and childhood
heritable screening programs, and
recommends conditions for inclusion in
the Recommended Uniform Screening
Panel (RUSP). The Committee’s
recommendations regarding additional
conditions/inherited disorders for
screening that have been adopted by the
Secretary are included in the RUSP and
constitute part of the comprehensive
guidelines supported by HRSA pursuant
to section 2713 of the PHSA, codified at
42 U.S.C. 300gg–13. Under this
provision, non-grandfathered health
plans and group and individual health
insurance issuers are required to cover
screenings included in the HRSAsupported comprehensive guidelines
without charging a co-payment, coinsurance, or deductible for plan years
(i.e., in the individual market, policy
years) beginning on or after the date that
is one (1) year from the Secretary’s
adoption of the condition for screening.
Nominations: HRSA is requesting
nominations to fill up to three (3)
positions for voting members to serve on
the Committee. The Secretary appoints
committee members with the expertise
needed to fulfill the duties of the
Committee established under section
1111(b) of the PHSA, as amended by the
Newborn Screening Saves Lives
Reauthorization Act of 2014 (Act; 42
U.S.C. 300b–10(b)). Areas of expertise
include medical, technical, or scientific
professionals with special expertise in
the field of heritable disorders or in
providing screening, counseling, testing,
or specialty services for newborns and
children with, or at risk for having,
heritable disorders; and/or who have
expertise in ethics (e.g., bioethics) and
infectious diseases and who have
worked and published material in the
area of newborn screening; and/or are
members of the public having special
expertise about or concern with
heritable disorders; and/or
VerDate Sep<11>2014
19:21 Apr 05, 2018
Jkt 244001
representatives from such federal
agencies, public health constituencies,
and medical professional societies.
Interested applicants may self-nominate
or be nominated by another individual
or organization. Nominees must reside
in the United States.
Individuals selected for appointment
to the Committee will be invited to
serve for up to four (4) years. Members
who are not federal officers or
permanent federal employees are
appointed as special government
employees and receive a stipend and
reimbursement for per diem and travel
expenses incurred for attending
Committee meetings and/or conducting
other business on behalf of the
Committee, as authorized by section 5
U.S.C. 5703 for persons employed
intermittently in government service.
Members who are officers or employees
of the United States Government shall
not receive additional compensation for
service on the Committee, but receive
per diem and travel expenses incurred
for attending Committee meetings and/
or conducting other business on behalf
of the Committee.
The following information must be
included in the package of materials
submitted for each individual being
nominated for consideration: (1) A
statement that includes the name and
affiliation of the nominee and a clear
statement regarding the basis for the
nomination, including the area(s) of
expertise that may qualify a nominee for
service on the Committee, as described
above; (2) confirmation the nominee is
willing to serve as a member of the
Committee; (3) the nominee’s contact
information (include home address,
work address, daytime telephone
number, and an email address); and (4)
a current copy of the nominee’s
curriculum vitae. Nomination packages
may be submitted directly by the
individual being nominated or by the
person/organization recommending the
candidate.
HHS will endeavor to ensure that the
membership of the Committee is fairly
balanced in terms of points of view
represented and that individuals from a
broad representation of geographic
areas, gender, ethnic and minority
groups, as well as individuals with
disabilities, are considered for
membership. Appointments shall be
made without discrimination on the
basis of age, ethnicity, gender, sexual
orientation, and cultural, religious, or
socioeconomic status.
Individuals who are selected to be
considered for appointment will be
required to provide detailed information
regarding their financial holdings,
consultancies, and research grants or
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
14867
contracts. Disclosure of this information
is necessary in order to determine if the
selected candidate is involved in any
activity that may pose a potential
conflict with the official duties to be
performed as a member of the
Committee.
Authority: Section 1111 of the Public
Health Service Act (PHSA), as amended by
the Newborn Screening Saves Lives
Reauthorization Act of 2014 (42 U.S.C. 300b–
10). The Committee is governed by the
Federal Advisory Committee Act (FACA), as
amended (5 U.S.C. App.), and 41 CFR part
102–3, which set forth standards for the
formation and use of advisory committees.
Dated: March 30, 2018.
Lori A. Roche,
Acting Deputy Director, Division of the
Executive Secretariat.
[FR Doc. 2018–07005 Filed 4–5–18; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee
on the Validation of Alternative
Methods; Notice of Public Meeting;
Request for Public Input
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Interagency Coordinating
Committee on the Validation of
Alternative Methods (ICCVAM) will
hold a public forum to share
information and facilitate direct
communication of ideas and suggestions
from stakeholders. Interested persons
may attend in person or view the
meeting remotely by webcast. Time will
be set aside for questions and public
statements on the topics discussed.
Registration is requested for both public
attendance and oral statements, and
required for remote access. Information
about the meeting and registration are
available at https://ntp.niehs.nih.gov/go/
iccvamforum-2018.
DATES:
Meeting: May 24, 2018, 9:00 a.m. to
approximately 4:00 p.m. Eastern
Daylight Time (EDT).
Registration for Onsite Meeting:
Deadline is May 11, 2018.
Registration for Webcast: Deadline is
May 24, 2018.
Submission of Oral Public Statements:
Deadline is May 11, 2018.
ADDRESSES: Meeting Location: William
H. Natcher Conference Center, National
Institutes of Health, Bethesda, MD
20892. Meeting web page: The
SUMMARY:
E:\FR\FM\06APN1.SGM
06APN1
14868
Federal Register / Vol. 83, No. 67 / Friday, April 6, 2018 / Notices
preliminary agenda, registration, and
other meeting materials are at https://
ntp.niehs.nih.gov/go/iccvamforum2018.
Dr.
Warren Casey, Director, National
Toxicology Program Interagency Center
for the Evaluation of Alternative
Toxicological Methods (NICEATM);
email: warren.casey@nih.gov; telephone:
(984) 287–3118.
SUPPLEMENTARY INFORMATION:
Background: ICCVAM, a
congressionally mandated committee,
promotes the development and
validation of alternative testing
strategies that protect human health and
the environment while replacing,
reducing, or refining animal use.
ICCVAM’s goals include promotion of
national and international partnerships
between governmental and
nongovernmental groups, including
academia, industry, advocacy groups,
and other key stakeholders. To foster
these partnerships ICCVAM initiated
annual public forums in 2014 to share
information and facilitate direct
communication of ideas and suggestions
from stakeholders (79 FR 25136).
This year’s meeting will be held on
May 24, 2018, at the National Institutes
of Health (NIH) in Bethesda, MD. The
meeting will include presentations by
NICEATM and ICCVAM members on
current activities related to the
development and validation of
alternative test methods and
approaches, including activities relevant
to implementation of the strategic
roadmap for establishing new
approaches to evaluate the safety of
chemicals and medical products in the
United States (83 FR 7487).
Following each presentation, there
will be an opportunity for participants
to ask questions of the ICCVAM
members. Instructions for submitting
questions will be provided to remote
participants prior to the webcast. The
agenda will also include time for
participants to make public oral
statements relevant to the ICCVAM
mission and current activities.
Preliminary Agenda and Other
Meeting Information: The preliminary
agenda, list of discussion topics,
background materials, ICCVAM roster,
and public statements submitted prior
to the meeting will be posted by May 17
at https://ntp.niehs.nih.gov/go/
iccvamforum-2018. Interested
individuals are encouraged to visit this
web page to stay abreast of the most
current meeting information.
Meeting and Registration: This
meeting is open to the public with time
scheduled for questions and oral public
daltland on DSKBBV9HB2PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Sep<11>2014
19:21 Apr 05, 2018
Jkt 244001
statements following presentations from
ICCVAM and NICEATM. The public
may attend the meeting at NIH, where
attendance is limited only by the space
available, or view remotely by webcast.
Those planning to attend the meeting in
person are encouraged to register at
https://ntp.niehs.nih.gov/go/
iccvamforum-2018 by May 11, 2018, to
facilitate planning for appropriate
meeting space. Those planning to view
the webcast must register at https://
ntp.niehs.nih.gov/go/iccvamforum2018; registration will be available
through May 24, 2018. The URL for the
webcast will be provided in the email
confirming registration.
NIH visitor and security information
is available at https://www.nih.gov/
about/visitor/index.htm. Individuals
with disabilities who need
accommodation to participate in this
event should contact Dr. Elizabeth
Maull at phone: (984) 287–3157 or
email: maull@niehs.nih.gov. TTY users
should contact the Federal TTY Relay
Service at 800–877–8339. Requests
should be made at least five business
days in advance of the event.
Request for Oral Public Statements:
Each presentation will be followed by
an opportunity for participants to ask
questions of the presenter. Attendees
need not register in advance for the
opportunity to ask questions or make
comments specific to presentations.
Instructions for submitting questions or
comments will be provided to remote
participants prior to the webcast.
In addition to time for questions or
comments following each scheduled
presentation, time will be allotted
during the meeting for oral public
statements with associated slides on
topics relevant to ICCVAM’s mission.
The number and length of presentations
may be limited based on available time.
Submitters will be identified by their
name and affiliation and/or sponsoring
organization, if applicable. Persons
submitting public statements and/or
associated slides should include their
name, affiliation (if any), mailing
address, telephone, email, and
sponsoring organization (if any) with
the document. National Toxicology
Program guidelines for public
statements are at https://
ntp.niehs.nih.gov/ntp/about_ntp/
guidelines_public_comments_508.pdf.
Persons wishing to present oral public
statements should email their statement
to ICCVAMquestions@niehs.nih.gov by
May 11, 2018, to allow time for review
by NICEATM and ICCVAM and posting
to the meeting page prior to the forum.
Written statements may supplement and
expand the oral presentation. Public
statements will be distributed to
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
NICEATM and ICCVAM members
before the meeting.
Registration for oral public statements
will be available onsite, although onsite
registration and time allotted for these
statements may be limited based on the
number of individuals who register to
make statements and available time. If
registering onsite and reading from
written text, please bring 20 copies of
the statement for distribution and to
supplement the record.
Persons wishing to present oral public
statements are strongly encouraged to
present their comments in person to
facilitate effective interaction with
ICCVAM members. However, there will
also be the opportunity to present
public statements by teleconference
line. Persons who are unable to attend
the meeting in person and wish to
present oral public statements should
email ICCVAMquestions@niehs.nih.gov
by May 11, 2018 to arrange to present
statements via teleconference line.
Responses to this notice are
voluntary. No proprietary, classified,
confidential, or sensitive information
should be included in statements
submitted in response to this notice or
presented during the meeting. This
request for input is for planning
purposes only and is not a solicitation
for applications or an obligation on the
part of the U.S. Government to provide
support for any ideas identified in
response to the request. Please note that
the U.S. Government will not pay for
the preparation of any information
submitted or for its use of that
information.
Background Information on ICCVAM
and NICEATM: ICCVAM is an
interagency committee composed of
representatives from 16 federal
regulatory and research agencies that
require, use, generate, or disseminate
toxicological and safety testing
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability. ICCVAM also
promotes the scientific validation and
regulatory acceptance of testing
methods that more accurately assess the
safety and hazards of chemicals and
products and replace, reduce, or refine
animal use. The ICCVAM Authorization
Act of 2000 (42 U.S.C. 285l–3)
establishes ICCVAM as a permanent
interagency committee of NIEHS and
provides the authority for ICCVAM
involvement in activities relevant to the
development of alternative test
methods. Additional information about
ICCVAM can be found at https://
ntp.niehs.nih.gov/go/iccvam.
E:\FR\FM\06APN1.SGM
06APN1
Federal Register / Vol. 83, No. 67 / Friday, April 6, 2018 / Notices
NICEATM administers ICCVAM,
provides scientific and operational
support for ICCVAM-related activities,
and conducts and publishes analyses
and evaluations of data from new,
revised, and alternative testing
approaches. NICEATM and ICCVAM
work collaboratively to evaluate new
and improved testing approaches
applicable to the needs of U.S. federal
agencies.
NICEATM and ICCVAM welcome the
public nomination of new, revised, and
alternative test methods and strategies
for validation studies and technical
evaluations. Additional information
about NICEATM can be found at https://
ntp.niehs.nih.gov/go/niceatm.
Dated: April 2, 2018.
Brian R. Berridge,
Associate Director, National Toxicology
Program.
[FR Doc. 2018–07057 Filed 4–5–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
daltland on DSKBBV9HB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel HIV
Neurodegeneration.
Date: May 30, 2018.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892.
Contact Person: Anita H. Undale, Ph.D.,
MD, Scientific Review Branch, National
Institute on Aging, Gateway Building, Suite
2W200, 7201 Wisconsin Avenue, Bethesda,
MD 20892, 240–747–7825, anita.undale@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
VerDate Sep<11>2014
19:21 Apr 05, 2018
Jkt 244001
Dated: April 3, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–07059 Filed 4–5–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; R25
Review.
Date: May 9, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W110, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Robert E. Bird, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W110,
Bethesda, MD 20892–9750 240–276–6344,
birdr@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–1: NCI
Clinical Translational R21 and Omnibus R03.
Date: May 17, 2018.
Time: 7:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Robert S. Coyne, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W236, Bethesda, MD
20892–9750, 240–276–5120, coyners@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Partnerships in Cancer Research (P20) and
Cancer Health Equity (U54).
Date: May 21–22, 2018.
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
14869
Time: 5:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Clifford W. Schweinfest,
Ph.D., Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W108,
Bethesda, MD 20892–9750, 240–276–633,
schweinfestcw@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–2: NCI
Clinical Translational R21 and Omnibus R03.
Date: May 21–22, 2018.
Time: 5:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Hasan Siddiqui, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W240 Bethesda, MD
20892–9750, 240–276–5122, hasan.siddiqui@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Transitional Fellowship.
Date: May 31–June 1, 2018.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Reed A. Graves, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W106, Bethesda, MD 20892–
9750, 240–276–6384, gravesr@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–6: NCI
Omnibus.
Date: June 1, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W649, Bethesda, MD
20892–9750, 240–276–5179, saejeong.kim@
nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
I—Transition to Independence.
Date: June 6–7, 2018.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Crystal City, 2799
Jefferson Davis Highway, Arlington, VA
22202.
Contact Person: Delia Tang, MD, Scientific
Review Officer, Research Programs Review
E:\FR\FM\06APN1.SGM
06APN1
]]>Agencies
[Federal Register Volume 83, Number 67 (Friday, April 6, 2018)]
[Notices]
[Pages 14867-14869]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-07057]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee on the Validation of
Alternative Methods; Notice of Public Meeting; Request for Public Input
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Interagency Coordinating Committee on the Validation of
Alternative Methods (ICCVAM) will hold a public forum to share
information and facilitate direct communication of ideas and
suggestions from stakeholders. Interested persons may attend in person
or view the meeting remotely by webcast. Time will be set aside for
questions and public statements on the topics discussed. Registration
is requested for both public attendance and oral statements, and
required for remote access. Information about the meeting and
registration are available at https://ntp.niehs.nih.gov/go/iccvamforum-2018.
DATES:
Meeting: May 24, 2018, 9:00 a.m. to approximately 4:00 p.m. Eastern
Daylight Time (EDT).
Registration for Onsite Meeting: Deadline is May 11, 2018.
Registration for Webcast: Deadline is May 24, 2018.
Submission of Oral Public Statements: Deadline is May 11, 2018.
ADDRESSES: Meeting Location: William H. Natcher Conference Center,
National Institutes of Health, Bethesda, MD 20892. Meeting web page:
The
[[Page 14868]]
preliminary agenda, registration, and other meeting materials are at
https://ntp.niehs.nih.gov/go/iccvamforum-2018.
FOR FURTHER INFORMATION CONTACT: Dr. Warren Casey, Director, National
Toxicology Program Interagency Center for the Evaluation of Alternative
Toxicological Methods (NICEATM); email: [email protected];
telephone: (984) 287-3118.
SUPPLEMENTARY INFORMATION:
Background: ICCVAM, a congressionally mandated committee, promotes
the development and validation of alternative testing strategies that
protect human health and the environment while replacing, reducing, or
refining animal use.
ICCVAM's goals include promotion of national and international
partnerships between governmental and nongovernmental groups, including
academia, industry, advocacy groups, and other key stakeholders. To
foster these partnerships ICCVAM initiated annual public forums in 2014
to share information and facilitate direct communication of ideas and
suggestions from stakeholders (79 FR 25136).
This year's meeting will be held on May 24, 2018, at the National
Institutes of Health (NIH) in Bethesda, MD. The meeting will include
presentations by NICEATM and ICCVAM members on current activities
related to the development and validation of alternative test methods
and approaches, including activities relevant to implementation of the
strategic roadmap for establishing new approaches to evaluate the
safety of chemicals and medical products in the United States (83 FR
7487).
Following each presentation, there will be an opportunity for
participants to ask questions of the ICCVAM members. Instructions for
submitting questions will be provided to remote participants prior to
the webcast. The agenda will also include time for participants to make
public oral statements relevant to the ICCVAM mission and current
activities.
Preliminary Agenda and Other Meeting Information: The preliminary
agenda, list of discussion topics, background materials, ICCVAM roster,
and public statements submitted prior to the meeting will be posted by
May 17 at https://ntp.niehs.nih.gov/go/iccvamforum-2018. Interested
individuals are encouraged to visit this web page to stay abreast of
the most current meeting information.
Meeting and Registration: This meeting is open to the public with
time scheduled for questions and oral public statements following
presentations from ICCVAM and NICEATM. The public may attend the
meeting at NIH, where attendance is limited only by the space
available, or view remotely by webcast. Those planning to attend the
meeting in person are encouraged to register at https://ntp.niehs.nih.gov/go/iccvamforum-2018 by May 11, 2018, to facilitate
planning for appropriate meeting space. Those planning to view the
webcast must register at https://ntp.niehs.nih.gov/go/iccvamforum-2018;
registration will be available through May 24, 2018. The URL for the
webcast will be provided in the email confirming registration.
NIH visitor and security information is available at https://www.nih.gov/about/visitor/index.htm. Individuals with disabilities who
need accommodation to participate in this event should contact Dr.
Elizabeth Maull at phone: (984) 287-3157 or email: [email protected].
TTY users should contact the Federal TTY Relay Service at 800-877-8339.
Requests should be made at least five business days in advance of the
event.
Request for Oral Public Statements: Each presentation will be
followed by an opportunity for participants to ask questions of the
presenter. Attendees need not register in advance for the opportunity
to ask questions or make comments specific to presentations.
Instructions for submitting questions or comments will be provided to
remote participants prior to the webcast.
In addition to time for questions or comments following each
scheduled presentation, time will be allotted during the meeting for
oral public statements with associated slides on topics relevant to
ICCVAM's mission. The number and length of presentations may be limited
based on available time. Submitters will be identified by their name
and affiliation and/or sponsoring organization, if applicable. Persons
submitting public statements and/or associated slides should include
their name, affiliation (if any), mailing address, telephone, email,
and sponsoring organization (if any) with the document. National
Toxicology Program guidelines for public statements are at https://ntp.niehs.nih.gov/ntp/about_ntp/guidelines_public_comments_508.pdf.
Persons wishing to present oral public statements should email
their statement to [email protected] by May 11, 2018, to
allow time for review by NICEATM and ICCVAM and posting to the meeting
page prior to the forum. Written statements may supplement and expand
the oral presentation. Public statements will be distributed to NICEATM
and ICCVAM members before the meeting.
Registration for oral public statements will be available onsite,
although onsite registration and time allotted for these statements may
be limited based on the number of individuals who register to make
statements and available time. If registering onsite and reading from
written text, please bring 20 copies of the statement for distribution
and to supplement the record.
Persons wishing to present oral public statements are strongly
encouraged to present their comments in person to facilitate effective
interaction with ICCVAM members. However, there will also be the
opportunity to present public statements by teleconference line.
Persons who are unable to attend the meeting in person and wish to
present oral public statements should email
[email protected] by May 11, 2018 to arrange to present
statements via teleconference line.
Responses to this notice are voluntary. No proprietary, classified,
confidential, or sensitive information should be included in statements
submitted in response to this notice or presented during the meeting.
This request for input is for planning purposes only and is not a
solicitation for applications or an obligation on the part of the U.S.
Government to provide support for any ideas identified in response to
the request. Please note that the U.S. Government will not pay for the
preparation of any information submitted or for its use of that
information.
Background Information on ICCVAM and NICEATM: ICCVAM is an
interagency committee composed of representatives from 16 federal
regulatory and research agencies that require, use, generate, or
disseminate toxicological and safety testing information. ICCVAM
conducts technical evaluations of new, revised, and alternative safety
testing methods and integrated testing strategies with regulatory
applicability. ICCVAM also promotes the scientific validation and
regulatory acceptance of testing methods that more accurately assess
the safety and hazards of chemicals and products and replace, reduce,
or refine animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C.
285l-3) establishes ICCVAM as a permanent interagency committee of
NIEHS and provides the authority for ICCVAM involvement in activities
relevant to the development of alternative test methods. Additional
information about ICCVAM can be found at https://ntp.niehs.nih.gov/go/iccvam.
[[Page 14869]]
NICEATM administers ICCVAM, provides scientific and operational
support for ICCVAM-related activities, and conducts and publishes
analyses and evaluations of data from new, revised, and alternative
testing approaches. NICEATM and ICCVAM work collaboratively to evaluate
new and improved testing approaches applicable to the needs of U.S.
federal agencies.
NICEATM and ICCVAM welcome the public nomination of new, revised,
and alternative test methods and strategies for validation studies and
technical evaluations. Additional information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/niceatm.
Dated: April 2, 2018.
Brian R. Berridge,
Associate Director, National Toxicology Program.
[FR Doc. 2018-07057 Filed 4-5-18; 8:45 am]
BILLING CODE 4140-01-P
